Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis
Fig 5
Systemic administration of 17-βE as a solution and a CREKA-peptide-modified nanoemulsion system alters atherosclerosis-related gene expression within the aorta and improves plasma lipid profile.
(A) The effect of 17-βE in solution, 17-βE in nanoemulsion, and the blank nanoemulsion on relative gene expression in ApoE-/- mice receiving a high-fat diet measured relative to gene expression in wild-type mice. The asterisk indicates statistical significance (P < 0.05) relative to the baseline gene expression measured in the wild-type mice. (n = 4 independent animals per group). (B) Total plasma cholesterol levels measured in the untreated and the different treatment groups at the beginning and end of the efficacy study. Values are represented as means ± SD (n = 6 independent animals per group). The asterisk represents significance between the untreated animals and the different treatment groups (P < 0.05). (C) Total plasma triglyceride levels measured in the untreated and the different treatment groups at the beginning and end of the efficacy study. Values are represented as means ± SD (n = 6 independent animals per group). The asterisk represents significance between the untreated animals and the different treatment groups (P < 0.05).
